This year's conference has expanded its focus from solely viral safety to encompass mycoplasma, TSE and bacteria. The event will have a strong focus on prevention and regulatory compliance as well as offering a nature of discussion based and interactive sessions.
Systematically Characterising Adventitious Agent Tests for Biologics
At the conference, Rebecca Sheets will be discussing the policy perspective on adapting new testing methodologies, she will assess the breadth and sensitivity of routine adventitious agent tests and will cover the harmonisation of test methods (both existing and emerging).
On the other hand, Santosh Nanda will be sharing a regulatory perspective on how to evaluate the Safety of New Flu Vaccine Development Methods, he will assess the risks of the cell-based development process and will also Investigate the challenges and benefits of utilising cell based vaccine development and developing regulatory guidance to govern the process.
The Ensuring Adventitious Agent Safety in Biologics conference aims at creating effective strategies to mitigate risk and enable prompt remediation of viral, prion and mycoplasma contamination - it will provide an interactive forum for learning best practices, keeping abreast of new developments and forging lasting business relationships.
20 biotech and biopharma experts are getting together this October to share updates and insights on how to escape contamination and get your products to market safely, speedily and successfully.
To view the conference programme (including full speaker and session information)
Find event details and registration information on
Media contact: Veronica Araujo, +44 (0)20 7368 9748, veronica.araujo@
Press are invited to attend this important industry forum, if you would like to a complimentary press pass please email Veronica Araujo (veronica.araujo@